Pain Management Drugs Market By Drug Class (NSAIDs, Anesthetics, Anticonvulsants, Anti-migraine Agents, Antidepressants, Opioids, Nonnarcotic Analgesics) , By Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Postoperative Pain, Migraine, Fibromyalgia, Muscle Sprain/Strain, Bone Fracture, Acute Appendicitis, Others) By Pain Type (Chronic Pain, Acute Pain) : Global Opportunity Analysis and Industry Forecast, 2024-2033
Pain Management Drugs Market
The pain management drugs market was valued at $72.6 billion in 2023 and is projected to reach $109.6 billion by 2033, growing at a CAGR of 4.2% from 2024 to 2033.
A pain management drug is medication prescribed for the alleviation of pain ranging from moderate discomfort to severe distress. The formulation of pain management drugs comprises of different drug class, including opioids, antidepressants or acetaminophen. These medications target diverse pain types, including musculoskeletal, neuropathic, and inflammatory pain. The mechanisms pertaining to the functioning of pain management drug are diverse such as lowering of inflammation, inhibition of pain signals in the nervous system, or alteration of brain chemistry to modulate the perception of pain.
Increase in the prevalence of lifestyle and chronic diseases such as stroke, heart disease, type II diabetes, and cancer is driving the pain management drugs market. In addition, advancements in drug formulations and delivery methods such as extended-release formulations with reduced dosing frequency are boosting the demand for the drugs as they enhance patient compliance & treatment outcomes. In recent times, explorations in nanotherapeutics are trending in the market as nanoparticles are anticipated to possess the capability of precisely identifying the target and offering long-term efficacy in significantly low dosage.
However, the severe side-effects of pain management drugs; including cardiovascular events, gastrointestinal bleeding, sedation, renal impairment, and respiratory depression; limit their consumption, hence presenting challenges for market expansion. To eliminate the hazards of conventional drugs, natural alternatives are being explored as they have potentially minimal to no side-effects. For instance, Kratom, a herbal substance obtained from the Mitragyna speciosa tree, is being utilized as an alternative to opioid drugs. Kratom medications have proved to be highly effective in providing relief from chronic pain conditions such as fibromyalgia & arthritis and neuropathic pain.
Segment Review
The pain management drugs market is segmented into drug class, indication, pain type, and region. On the basis of drug class, the market is divided into NSAIDs, anesthetics, anticonvulsants, anti-migraine agents, antidepressants, opioids, and nonnarcotic analgesics. As per indication, it is classified into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, fibromyalgia, muscle sprain/strain, bone fracture, acute appendicitis, and others. By pain type, it is bifurcated into chronic pain and acute pain. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of drug class, the opioids segment is expected to dominate the market during the forecast period.
As per indication, the postoperative pain segment is predicted to be the highest shareholder by 2033.
By pain type, the chronic pain segment is anticipated to lead the market during the forecast period.
Region wise, North America is projected to be the highest revenue generator by 2033.
Competition Analysis
The major players operating in the global pain management drugs market include Novartis AG, Eli Lilly & Company, Abbott Laboratories, Endo Health Solutions, Inc., Purdue Pharma L.P., Pfizer, Inc., Viatris Inc., Merck & Co. Inc., Johnson & Johnson, and GlaxoSmithKline Plc. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.
Key Market Segments
By Drug Class
NSAIDs
Anesthetics
Anticonvulsants
Anti-migraine Agents
Antidepressants
Opioids
Nonnarcotic Analgesics
By Indication
Arthritic Pain
Neuropathic Pain
Cancer Pain
Chronic Back Pain
Postoperative Pain
Migraine
Fibromyalgia
Muscle Sprain/Strain
Bone Fracture
Acute Appendicitis
Others
By Pain Type
Chronic Pain
Acute Pain
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Novartis AG
Eli Lilly & Company
Abbott Laboratories
Endo Health Solutions, Inc.
Purdue Pharma L.P.
Pfizer, Inc.
Viatris Inc.
Merck & Co. Inc.
Johnson & Johnson
GlaxoSmithKline Plc
- CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET LANDSCAPE
- 3.1. Market Definition and Scope
- 3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
- 3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities
- CHAPTER 4: PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS
- 4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Drug Class
- 4.2. NSAIDs
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.3. Anesthetics
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
- 4.4. Anticonvulsants
- 4.4.1. Key Market Trends, Growth Factors and Opportunities
- 4.4.2. Market Size and Forecast, By Region
- 4.4.3. Market Share Analysis, By Country
- 4.5. Anti-migraine Agents
- 4.5.1. Key Market Trends, Growth Factors and Opportunities
- 4.5.2. Market Size and Forecast, By Region
- 4.5.3. Market Share Analysis, By Country
- 4.6. Antidepressants
- 4.6.1. Key Market Trends, Growth Factors and Opportunities
- 4.6.2. Market Size and Forecast, By Region
- 4.6.3. Market Share Analysis, By Country
- 4.7. Opioids
- 4.7.1. Key Market Trends, Growth Factors and Opportunities
- 4.7.2. Market Size and Forecast, By Region
- 4.7.3. Market Share Analysis, By Country
- 4.8. Nonnarcotic Analgesics
- 4.8.1. Key Market Trends, Growth Factors and Opportunities
- 4.8.2. Market Size and Forecast, By Region
- 4.8.3. Market Share Analysis, By Country
- CHAPTER 5: PAIN MANAGEMENT DRUGS MARKET, BY INDICATION
- 5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Indication
- 5.2. Arthritic Pain
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
- 5.3. Neuropathic Pain
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
- 5.4. Cancer Pain
- 5.4.1. Key Market Trends, Growth Factors and Opportunities
- 5.4.2. Market Size and Forecast, By Region
- 5.4.3. Market Share Analysis, By Country
- 5.5. Chronic Back Pain
- 5.5.1. Key Market Trends, Growth Factors and Opportunities
- 5.5.2. Market Size and Forecast, By Region
- 5.5.3. Market Share Analysis, By Country
- 5.6. Postoperative Pain
- 5.6.1. Key Market Trends, Growth Factors and Opportunities
- 5.6.2. Market Size and Forecast, By Region
- 5.6.3. Market Share Analysis, By Country
- 5.7. Migraine
- 5.7.1. Key Market Trends, Growth Factors and Opportunities
- 5.7.2. Market Size and Forecast, By Region
- 5.7.3. Market Share Analysis, By Country
- 5.8. Fibromyalgia
- 5.8.1. Key Market Trends, Growth Factors and Opportunities
- 5.8.2. Market Size and Forecast, By Region
- 5.8.3. Market Share Analysis, By Country
- 5.9. Muscle Sprain/Strain
- 5.9.1. Key Market Trends, Growth Factors and Opportunities
- 5.9.2. Market Size and Forecast, By Region
- 5.9.3. Market Share Analysis, By Country
- 5.10. Bone Fracture
- 5.10.1. Key Market Trends, Growth Factors and Opportunities
- 5.10.2. Market Size and Forecast, By Region
- 5.10.3. Market Share Analysis, By Country
- 5.11. Acute Appendicitis
- 5.11.1. Key Market Trends, Growth Factors and Opportunities
- 5.11.2. Market Size and Forecast, By Region
- 5.11.3. Market Share Analysis, By Country
- 5.12. Others
- 5.12.1. Key Market Trends, Growth Factors and Opportunities
- 5.12.2. Market Size and Forecast, By Region
- 5.12.3. Market Share Analysis, By Country
- CHAPTER 6: PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE
- 6.1. Market Overview
- 6.1.1 Market Size and Forecast, By Pain Type
- 6.2. Chronic Pain
- 6.2.1. Key Market Trends, Growth Factors and Opportunities
- 6.2.2. Market Size and Forecast, By Region
- 6.2.3. Market Share Analysis, By Country
- 6.3. Acute Pain
- 6.3.1. Key Market Trends, Growth Factors and Opportunities
- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country
- CHAPTER 7: PAIN MANAGEMENT DRUGS MARKET, BY REGION
- 7.1. Market Overview
- 7.1.1 Market Size and Forecast, By Region
- 7.2. North America
- 7.2.1. Key Market Trends and Opportunities
- 7.2.2. Market Size and Forecast, By Drug Class
- 7.2.3. Market Size and Forecast, By Indication
- 7.2.4. Market Size and Forecast, By Pain Type
- 7.2.5. Market Size and Forecast, By Country
- 7.2.6. U.S. Pain Management Drugs Market
- 7.2.6.1. Market Size and Forecast, By Drug Class
- 7.2.6.2. Market Size and Forecast, By Indication
- 7.2.6.3. Market Size and Forecast, By Pain Type
- 7.2.7. Canada Pain Management Drugs Market
- 7.2.7.1. Market Size and Forecast, By Drug Class
- 7.2.7.2. Market Size and Forecast, By Indication
- 7.2.7.3. Market Size and Forecast, By Pain Type
- 7.2.8. Mexico Pain Management Drugs Market
- 7.2.8.1. Market Size and Forecast, By Drug Class
- 7.2.8.2. Market Size and Forecast, By Indication
- 7.2.8.3. Market Size and Forecast, By Pain Type
- 7.3. Europe
- 7.3.1. Key Market Trends and Opportunities
- 7.3.2. Market Size and Forecast, By Drug Class
- 7.3.3. Market Size and Forecast, By Indication
- 7.3.4. Market Size and Forecast, By Pain Type
- 7.3.5. Market Size and Forecast, By Country
- 7.3.6. Germany Pain Management Drugs Market
- 7.3.6.1. Market Size and Forecast, By Drug Class
- 7.3.6.2. Market Size and Forecast, By Indication
- 7.3.6.3. Market Size and Forecast, By Pain Type
- 7.3.7. France Pain Management Drugs Market
- 7.3.7.1. Market Size and Forecast, By Drug Class
- 7.3.7.2. Market Size and Forecast, By Indication
- 7.3.7.3. Market Size and Forecast, By Pain Type
- 7.3.8. UK Pain Management Drugs Market
- 7.3.8.1. Market Size and Forecast, By Drug Class
- 7.3.8.2. Market Size and Forecast, By Indication
- 7.3.8.3. Market Size and Forecast, By Pain Type
- 7.3.9. Italy Pain Management Drugs Market
- 7.3.9.1. Market Size and Forecast, By Drug Class
- 7.3.9.2. Market Size and Forecast, By Indication
- 7.3.9.3. Market Size and Forecast, By Pain Type
- 7.3.10. Spain Pain Management Drugs Market
- 7.3.10.1. Market Size and Forecast, By Drug Class
- 7.3.10.2. Market Size and Forecast, By Indication
- 7.3.10.3. Market Size and Forecast, By Pain Type
- 7.3.11. Rest Of Europe Pain Management Drugs Market
- 7.3.11.1. Market Size and Forecast, By Drug Class
- 7.3.11.2. Market Size and Forecast, By Indication
- 7.3.11.3. Market Size and Forecast, By Pain Type
- 7.4. Asia-Pacific
- 7.4.1. Key Market Trends and Opportunities
- 7.4.2. Market Size and Forecast, By Drug Class
- 7.4.3. Market Size and Forecast, By Indication
- 7.4.4. Market Size and Forecast, By Pain Type
- 7.4.5. Market Size and Forecast, By Country
- 7.4.6. Japan Pain Management Drugs Market
- 7.4.6.1. Market Size and Forecast, By Drug Class
- 7.4.6.2. Market Size and Forecast, By Indication
- 7.4.6.3. Market Size and Forecast, By Pain Type
- 7.4.7. China Pain Management Drugs Market
- 7.4.7.1. Market Size and Forecast, By Drug Class
- 7.4.7.2. Market Size and Forecast, By Indication
- 7.4.7.3. Market Size and Forecast, By Pain Type
- 7.4.8. India Pain Management Drugs Market
- 7.4.8.1. Market Size and Forecast, By Drug Class
- 7.4.8.2. Market Size and Forecast, By Indication
- 7.4.8.3. Market Size and Forecast, By Pain Type
- 7.4.9. Australia Pain Management Drugs Market
- 7.4.9.1. Market Size and Forecast, By Drug Class
- 7.4.9.2. Market Size and Forecast, By Indication
- 7.4.9.3. Market Size and Forecast, By Pain Type
- 7.4.10. South Korea Pain Management Drugs Market
- 7.4.10.1. Market Size and Forecast, By Drug Class
- 7.4.10.2. Market Size and Forecast, By Indication
- 7.4.10.3. Market Size and Forecast, By Pain Type
- 7.4.11. Rest of Asia-Pacific Pain Management Drugs Market
- 7.4.11.1. Market Size and Forecast, By Drug Class
- 7.4.11.2. Market Size and Forecast, By Indication
- 7.4.11.3. Market Size and Forecast, By Pain Type
- 7.5. LAMEA
- 7.5.1. Key Market Trends and Opportunities
- 7.5.2. Market Size and Forecast, By Drug Class
- 7.5.3. Market Size and Forecast, By Indication
- 7.5.4. Market Size and Forecast, By Pain Type
- 7.5.5. Market Size and Forecast, By Country
- 7.5.6. Brazil Pain Management Drugs Market
- 7.5.6.1. Market Size and Forecast, By Drug Class
- 7.5.6.2. Market Size and Forecast, By Indication
- 7.5.6.3. Market Size and Forecast, By Pain Type
- 7.5.7. Saudi Arabia Pain Management Drugs Market
- 7.5.7.1. Market Size and Forecast, By Drug Class
- 7.5.7.2. Market Size and Forecast, By Indication
- 7.5.7.3. Market Size and Forecast, By Pain Type
- 7.5.8. South Africa Pain Management Drugs Market
- 7.5.8.1. Market Size and Forecast, By Drug Class
- 7.5.8.2. Market Size and Forecast, By Indication
- 7.5.8.3. Market Size and Forecast, By Pain Type
- 7.5.9. Rest of LAMEA Pain Management Drugs Market
- 7.5.9.1. Market Size and Forecast, By Drug Class
- 7.5.9.2. Market Size and Forecast, By Indication
- 7.5.9.3. Market Size and Forecast, By Pain Type
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top Winning Strategies
- 8.3. Product Mapping Of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top Player Positioning, 2023
- CHAPTER 9: COMPANY PROFILES
- 9.1. Novartis AG
- 9.1.1. Company Overview
- 9.1.2. Key Executives
- 9.1.3. Company Snapshot
- 9.1.4. Operating Business Segments
- 9.1.5. Product Portfolio
- 9.1.6. Business Performance
- 9.1.7. Key Strategic Moves and Developments
- 9.2. Eli Lilly And Company
- 9.2.1. Company Overview
- 9.2.2. Key Executives
- 9.2.3. Company Snapshot
- 9.2.4. Operating Business Segments
- 9.2.5. Product Portfolio
- 9.2.6. Business Performance
- 9.2.7. Key Strategic Moves and Developments
- 9.3. Abbott Laboratories
- 9.3.1. Company Overview
- 9.3.2. Key Executives
- 9.3.3. Company Snapshot
- 9.3.4. Operating Business Segments
- 9.3.5. Product Portfolio
- 9.3.6. Business Performance
- 9.3.7. Key Strategic Moves and Developments
- 9.4. Endo Health Solutions, Inc.
- 9.4.1. Company Overview
- 9.4.2. Key Executives
- 9.4.3. Company Snapshot
- 9.4.4. Operating Business Segments
- 9.4.5. Product Portfolio
- 9.4.6. Business Performance
- 9.4.7. Key Strategic Moves and Developments
- 9.5. Purdue Pharma L.P.
- 9.5.1. Company Overview
- 9.5.2. Key Executives
- 9.5.3. Company Snapshot
- 9.5.4. Operating Business Segments
- 9.5.5. Product Portfolio
- 9.5.6. Business Performance
- 9.5.7. Key Strategic Moves and Developments
- 9.6. Pfizer, Inc.
- 9.6.1. Company Overview
- 9.6.2. Key Executives
- 9.6.3. Company Snapshot
- 9.6.4. Operating Business Segments
- 9.6.5. Product Portfolio
- 9.6.6. Business Performance
- 9.6.7. Key Strategic Moves and Developments
- 9.7. Viatris Inc.
- 9.7.1. Company Overview
- 9.7.2. Key Executives
- 9.7.3. Company Snapshot
- 9.7.4. Operating Business Segments
- 9.7.5. Product Portfolio
- 9.7.6. Business Performance
- 9.7.7. Key Strategic Moves and Developments
- 9.8. Merck And Co. Inc.
- 9.8.1. Company Overview
- 9.8.2. Key Executives
- 9.8.3. Company Snapshot
- 9.8.4. Operating Business Segments
- 9.8.5. Product Portfolio
- 9.8.6. Business Performance
- 9.8.7. Key Strategic Moves and Developments
- 9.9. Johnson And Johnson
- 9.9.1. Company Overview
- 9.9.2. Key Executives
- 9.9.3. Company Snapshot
- 9.9.4. Operating Business Segments
- 9.9.5. Product Portfolio
- 9.9.6. Business Performance
- 9.9.7. Key Strategic Moves and Developments
- 9.10. GlaxoSmithKline Plc
- 9.10.1. Company Overview
- 9.10.2. Key Executives
- 9.10.3. Company Snapshot
- 9.10.4. Operating Business Segments
- 9.10.5. Product Portfolio
- 9.10.6. Business Performance
- 9.10.7. Key Strategic Moves and Developments
- TABLE 1. GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 2. PAIN MANAGEMENT DRUGS MARKET FOR NSAIDS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 3. PAIN MANAGEMENT DRUGS MARKET FOR ANESTHETICS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 4. PAIN MANAGEMENT DRUGS MARKET FOR ANTICONVULSANTS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 5. PAIN MANAGEMENT DRUGS MARKET FOR ANTI-MIGRAINE AGENTS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 6. PAIN MANAGEMENT DRUGS MARKET FOR ANTIDEPRESSANTS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 7. PAIN MANAGEMENT DRUGS MARKET FOR OPIOIDS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 8. PAIN MANAGEMENT DRUGS MARKET FOR NONNARCOTIC ANALGESICS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 9. GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 10. PAIN MANAGEMENT DRUGS MARKET FOR ARTHRITIC PAIN, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 11. PAIN MANAGEMENT DRUGS MARKET FOR NEUROPATHIC PAIN, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 12. PAIN MANAGEMENT DRUGS MARKET FOR CANCER PAIN, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 13. PAIN MANAGEMENT DRUGS MARKET FOR CHRONIC BACK PAIN, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 14. PAIN MANAGEMENT DRUGS MARKET FOR POSTOPERATIVE PAIN, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 15. PAIN MANAGEMENT DRUGS MARKET FOR MIGRAINE, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 16. PAIN MANAGEMENT DRUGS MARKET FOR FIBROMYALGIA, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 17. PAIN MANAGEMENT DRUGS MARKET FOR MUSCLE SPRAIN/STRAIN, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 18. PAIN MANAGEMENT DRUGS MARKET FOR BONE FRACTURE, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 19. PAIN MANAGEMENT DRUGS MARKET FOR ACUTE APPENDICITIS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 20. PAIN MANAGEMENT DRUGS MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 21. GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2024 - 2033 ($BILLION)
- TABLE 22. PAIN MANAGEMENT DRUGS MARKET FOR CHRONIC PAIN, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 23. PAIN MANAGEMENT DRUGS MARKET FOR ACUTE PAIN, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 24. PAIN MANAGEMENT DRUGS MARKET, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 25. NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 26. NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 27. NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 28. NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2024 - 2033 ($BILLION)
- TABLE 29. U.S. PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 30. U.S. PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 31. U.S. PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2024 - 2033 ($BILLION)
- TABLE 32. CANADA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 33. CANADA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 34. CANADA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2024 - 2033 ($BILLION)
- TABLE 35. MEXICO PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 36. MEXICO PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 37. MEXICO PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2024 - 2033 ($BILLION)
- TABLE 38. EUROPE PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 39. EUROPE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 40. EUROPE PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 41. EUROPE PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2024 - 2033 ($BILLION)
- TABLE 42. GERMANY PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 43. GERMANY PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 44. GERMANY PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2024 - 2033 ($BILLION)
- TABLE 45. FRANCE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 46. FRANCE PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 47. FRANCE PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2024 - 2033 ($BILLION)
- TABLE 48. UK PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 49. UK PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 50. UK PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2024 - 2033 ($BILLION)
- TABLE 51. ITALY PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 52. ITALY PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 53. ITALY PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2024 - 2033 ($BILLION)
- TABLE 54. SPAIN PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 55. SPAIN PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 56. SPAIN PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2024 - 2033 ($BILLION)
- TABLE 57. REST OF EUROPE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 58. REST OF EUROPE PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 59. REST OF EUROPE PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2024 - 2033 ($BILLION)
- TABLE 60. ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 61. ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 62. ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 63. ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2024 - 2033 ($BILLION)
- TABLE 64. JAPAN PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 65. JAPAN PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 66. JAPAN PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2024 - 2033 ($BILLION)
- TABLE 67. CHINA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 68. CHINA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 69. CHINA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2024 - 2033 ($BILLION)
- TABLE 70. INDIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 71. INDIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 72. INDIA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2024 - 2033 ($BILLION)
- TABLE 73. AUSTRALIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 74. AUSTRALIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 75. AUSTRALIA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2024 - 2033 ($BILLION)
- TABLE 76. SOUTH KOREA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 77. SOUTH KOREA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 78. SOUTH KOREA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2024 - 2033 ($BILLION)
- TABLE 79. REST OF ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 80. REST OF ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 81. REST OF ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2024 - 2033 ($BILLION)
- TABLE 82. LAMEA PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 83. LAMEA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 84. LAMEA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 85. LAMEA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2024 - 2033 ($BILLION)
- TABLE 86. BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 87. BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 88. BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2024 - 2033 ($BILLION)
- TABLE 89. SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 90. SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 91. SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2024 - 2033 ($BILLION)
- TABLE 92. SOUTH AFRICA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 93. SOUTH AFRICA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 94. SOUTH AFRICA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2024 - 2033 ($BILLION)
- TABLE 95. REST OF LAMEA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2024 - 2033 ($BILLION)
- TABLE 96. REST OF LAMEA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 97. REST OF LAMEA PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2024 - 2033 ($BILLION)
- TABLE 98. NOVARTIS AG: KEY EXECUTIVES
- TABLE 99. NOVARTIS AG: COMPANY SNAPSHOT
- TABLE 100. NOVARTIS AG: OPERATING SEGMENTS
- TABLE 101. NOVARTIS AG: PRODUCT PORTFOLIO
- TABLE 102. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 103. ELI LILLY AND COMPANY: KEY EXECUTIVES
- TABLE 104. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
- TABLE 105. ELI LILLY AND COMPANY: OPERATING SEGMENTS
- TABLE 106. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
- TABLE 107. ELI LILLY AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 108. ABBOTT LABORATORIES: KEY EXECUTIVES
- TABLE 109. ABBOTT LABORATORIES: COMPANY SNAPSHOT
- TABLE 110. ABBOTT LABORATORIES: OPERATING SEGMENTS
- TABLE 111. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
- TABLE 112. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 113. ENDO HEALTH SOLUTIONS, INC.: KEY EXECUTIVES
- TABLE 114. ENDO HEALTH SOLUTIONS, INC.: COMPANY SNAPSHOT
- TABLE 115. ENDO HEALTH SOLUTIONS, INC.: OPERATING SEGMENTS
- TABLE 116. ENDO HEALTH SOLUTIONS, INC.: PRODUCT PORTFOLIO
- TABLE 117. ENDO HEALTH SOLUTIONS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 118. PURDUE PHARMA L.P.: KEY EXECUTIVES
- TABLE 119. PURDUE PHARMA L.P.: COMPANY SNAPSHOT
- TABLE 120. PURDUE PHARMA L.P.: OPERATING SEGMENTS
- TABLE 121. PURDUE PHARMA L.P.: PRODUCT PORTFOLIO
- TABLE 122. PURDUE PHARMA L.P.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 123. PFIZER, INC.: KEY EXECUTIVES
- TABLE 124. PFIZER, INC.: COMPANY SNAPSHOT
- TABLE 125. PFIZER, INC.: OPERATING SEGMENTS
- TABLE 126. PFIZER, INC.: PRODUCT PORTFOLIO
- TABLE 127. PFIZER, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 128. VIATRIS INC.: KEY EXECUTIVES
- TABLE 129. VIATRIS INC.: COMPANY SNAPSHOT
- TABLE 130. VIATRIS INC.: OPERATING SEGMENTS
- TABLE 131. VIATRIS INC.: PRODUCT PORTFOLIO
- TABLE 132. VIATRIS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 133. MERCK AND CO. INC.: KEY EXECUTIVES
- TABLE 134. MERCK AND CO. INC.: COMPANY SNAPSHOT
- TABLE 135. MERCK AND CO. INC.: OPERATING SEGMENTS
- TABLE 136. MERCK AND CO. INC.: PRODUCT PORTFOLIO
- TABLE 137. MERCK AND CO. INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 138. JOHNSON AND JOHNSON: KEY EXECUTIVES
- TABLE 139. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
- TABLE 140. JOHNSON AND JOHNSON: OPERATING SEGMENTS
- TABLE 141. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
- TABLE 142. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 143. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
- TABLE 144. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
- TABLE 145. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
- TABLE 146. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
- TABLE 147. GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
- FIGURE 1. GLOBAL PAIN MANAGEMENT DRUGS MARKET, 2024 - 2033
- FIGURE 2. SEGMENTATION OF PAIN MANAGEMENT DRUGS MARKET, 2024 - 2033
- FIGURE 3. TOP INVESTMENT POCKET IN PAIN MANAGEMENT DRUGS MARKET
- FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
- FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
- FIGURE 7. LOW THREAT OF SUBSTITUTION
- FIGURE 8. HIGH COMPETITIVE RIVALRY
- FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALPAIN MANAGEMENT DRUGS MARKET
- FIGURE 10. GLOBAL PAIN MANAGEMENT DRUGS MARKET SEGMENTATION, BY DRUG CLASS
- FIGURE 11. PAIN MANAGEMENT DRUGS MARKET FOR NSAIDS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 12. PAIN MANAGEMENT DRUGS MARKET FOR ANESTHETICS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 13. PAIN MANAGEMENT DRUGS MARKET FOR ANTICONVULSANTS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 14. PAIN MANAGEMENT DRUGS MARKET FOR ANTI-MIGRAINE AGENTS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 15. PAIN MANAGEMENT DRUGS MARKET FOR ANTIDEPRESSANTS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 16. PAIN MANAGEMENT DRUGS MARKET FOR OPIOIDS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 17. PAIN MANAGEMENT DRUGS MARKET FOR NONNARCOTIC ANALGESICS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 18. GLOBAL PAIN MANAGEMENT DRUGS MARKET SEGMENTATION, BY INDICATION
- FIGURE 19. PAIN MANAGEMENT DRUGS MARKET FOR ARTHRITIC PAIN, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 20. PAIN MANAGEMENT DRUGS MARKET FOR NEUROPATHIC PAIN, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 21. PAIN MANAGEMENT DRUGS MARKET FOR CANCER PAIN, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 22. PAIN MANAGEMENT DRUGS MARKET FOR CHRONIC BACK PAIN, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 23. PAIN MANAGEMENT DRUGS MARKET FOR POSTOPERATIVE PAIN, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 24. PAIN MANAGEMENT DRUGS MARKET FOR MIGRAINE, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 25. PAIN MANAGEMENT DRUGS MARKET FOR FIBROMYALGIA, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 26. PAIN MANAGEMENT DRUGS MARKET FOR MUSCLE SPRAIN/STRAIN, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 27. PAIN MANAGEMENT DRUGS MARKET FOR BONE FRACTURE, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 28. PAIN MANAGEMENT DRUGS MARKET FOR ACUTE APPENDICITIS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 29. PAIN MANAGEMENT DRUGS MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 30. GLOBAL PAIN MANAGEMENT DRUGS MARKET SEGMENTATION, BY PAIN TYPE
- FIGURE 31. PAIN MANAGEMENT DRUGS MARKET FOR CHRONIC PAIN, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 32. PAIN MANAGEMENT DRUGS MARKET FOR ACUTE PAIN, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 33. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
- FIGURE 34. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
- FIGURE 35. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
- FIGURE 36. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 37. COMPETITIVE DASHBOARD
- FIGURE 38. COMPETITIVE HEATMAP: PAIN MANAGEMENT DRUGS MARKET
- FIGURE 39. TOP PLAYER POSITIONING, 2023
- FIGURE 40. NOVARTIS AG: NET SALES, 2021-2023 ($BILLION)
- FIGURE 41. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 42. NOVARTIS AG: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 43. ELI LILLY AND COMPANY: NET SALES, 2021-2023 ($BILLION)
- FIGURE 44. ELI LILLY AND COMPANY: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 45. ELI LILLY AND COMPANY: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 46. ABBOTT LABORATORIES: NET SALES, 2021-2023 ($BILLION)
- FIGURE 47. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 48. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 49. ENDO HEALTH SOLUTIONS, INC.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 50. ENDO HEALTH SOLUTIONS, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 51. ENDO HEALTH SOLUTIONS, INC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 52. PURDUE PHARMA L.P.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 53. PURDUE PHARMA L.P.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 54. PURDUE PHARMA L.P.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 55. PFIZER, INC.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 56. PFIZER, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 57. PFIZER, INC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 58. VIATRIS INC.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 59. VIATRIS INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 60. VIATRIS INC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 61. MERCK AND CO. INC.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 62. MERCK AND CO. INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 63. MERCK AND CO. INC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 64. JOHNSON AND JOHNSON: NET SALES, 2021-2023 ($BILLION)
- FIGURE 65. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 66. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 67. GLAXOSMITHKLINE PLC: NET SALES, 2021-2023 ($BILLION)
- FIGURE 68. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 69. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY REGION, 2023 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook